Text Size

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study

Hori Y, Oka K, Inai M.


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Toho University Omori Medical Center, Toho University Graduate School of Medicine, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan; Global Clinical Development and Operations, Product Development Division, Clinical Operations Japan/Asia, Santen Pharmaceutical Co., Ltd., Kita-ku, Ofukacho Osaka, Japan

Related Publications

Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.


Multimodal Approach in Dry Eye Disease Combining In Vivo Confocal Microscopy and HLA-DR Expression

Blautain, B.; Rabut, G.; Dupas, B.; Riancho, L.; Liang, H.; Luzu, J.: Labbé, A.; Garrigue J.-S.; Brignole-Baudouin, F.; Baudouin, C.; Kessal, K.


Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022